CL2021002847A1 - Terapias de combinación que comprenden inhibidores de apremilast y tyk2 - Google Patents
Terapias de combinación que comprenden inhibidores de apremilast y tyk2Info
- Publication number
- CL2021002847A1 CL2021002847A1 CL2021002847A CL2021002847A CL2021002847A1 CL 2021002847 A1 CL2021002847 A1 CL 2021002847A1 CL 2021002847 A CL2021002847 A CL 2021002847A CL 2021002847 A CL2021002847 A CL 2021002847A CL 2021002847 A1 CL2021002847 A1 CL 2021002847A1
- Authority
- CL
- Chile
- Prior art keywords
- apremilast
- combination therapies
- tyk2 inhibitors
- tyk2
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Se proporcionan en la presente métodos para tratar enfermedades y trastornos que responden a la inhibición de PDE4 que comprende administrar apremilast y un inhibidor de Tyk2 a un sujeto. También se proporcionan en la presente composiciones farmacéuticas que comprenden apremilast y un inhibidor de Tyk2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/029772 WO2020222773A1 (en) | 2019-04-30 | 2019-04-30 | Combination therapies comprising apremilast and tyk2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021002847A1 true CL2021002847A1 (es) | 2022-07-22 |
Family
ID=66476870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021002847A CL2021002847A1 (es) | 2019-04-30 | 2021-10-29 | Terapias de combinación que comprenden inhibidores de apremilast y tyk2 |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP3962475A1 (es) |
JP (2) | JP2022537877A (es) |
KR (2) | KR20220002488A (es) |
CN (2) | CN114269336A (es) |
AU (2) | AU2019443366A1 (es) |
BR (2) | BR112021021809A2 (es) |
CA (2) | CA3138473A1 (es) |
CL (1) | CL2021002847A1 (es) |
CO (2) | CO2021015614A2 (es) |
IL (2) | IL287665A (es) |
MA (1) | MA55799A (es) |
MX (2) | MX2021013317A (es) |
SG (2) | SG11202112043PA (es) |
WO (2) | WO2020222773A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020222773A1 (en) | 2019-04-30 | 2020-11-05 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
IL305165A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | TYK2 inhibitors and their uses |
WO2023049241A1 (en) * | 2021-09-23 | 2023-03-30 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
US8367689B2 (en) * | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
AU2011328237A1 (en) | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
WO2012149251A1 (en) * | 2011-04-28 | 2012-11-01 | Celgene Corporation | Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases |
BR112014015923B1 (pt) * | 2011-12-27 | 2022-02-01 | Amgen (Europe) GmbH | Comprimidos revestidos de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metano-sulfoniletil]-4 - acetilaminoisoindolina-1,3-diona |
CN104159891B (zh) | 2012-01-10 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | 哒嗪酰胺化合物和它们作为syk 抑制剂的用途 |
WO2013146963A1 (ja) | 2012-03-28 | 2013-10-03 | 武田薬品工業株式会社 | 複素環化合物 |
CA2875990A1 (en) | 2012-05-24 | 2013-11-28 | Cellzome Limited | Heterocyclyl pyrimidine analogues as tyk2 inhibitors |
JP6407159B2 (ja) | 2012-11-08 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なアミド置換ヘテロ環式化合物 |
AU2013341195B2 (en) | 2012-11-08 | 2017-09-21 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNalpha |
KR20150126618A (ko) * | 2013-03-14 | 2015-11-12 | 셀진 코포레이션 | 아프레밀라스트를 사용하는 건선성 관절염의 치료 |
US20160159773A1 (en) | 2013-07-30 | 2016-06-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
RU2652795C2 (ru) | 2013-09-03 | 2018-05-03 | Сареум Лимитед | Производные 2-фенил-оксазол-4-карбоксамида, модулирующие активность jak и tyk2 киназ |
TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物 |
US10273237B2 (en) | 2013-12-10 | 2019-04-30 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses |
WO2015091584A1 (en) | 2013-12-18 | 2015-06-25 | F. Hoffmann-La Roche Ag | Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors |
US9834548B2 (en) * | 2014-02-14 | 2017-12-05 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as JAK inhibitors |
US9340540B2 (en) | 2014-02-28 | 2016-05-17 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
MX2016014384A (es) * | 2014-06-23 | 2017-01-20 | Celgene Corp | Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado. |
WO2016025686A1 (en) * | 2014-08-15 | 2016-02-18 | Celgene Corporation | Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition |
NO2721710T3 (es) | 2014-08-21 | 2018-03-31 | ||
WO2016047678A1 (ja) | 2014-09-25 | 2016-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
US20160251376A1 (en) | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
EP4327809A3 (en) | 2015-09-02 | 2024-04-17 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
JP6505956B2 (ja) | 2016-02-24 | 2019-04-24 | ファイザー・インク | JAK阻害剤としてのピラゾロ[1,5−a]ピラジン−4−イル誘導体 |
US10836770B2 (en) | 2016-10-07 | 2020-11-17 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses |
TWI763722B (zh) | 2016-10-14 | 2022-05-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
AU2017345736B2 (en) | 2016-10-21 | 2022-04-07 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
MA46620A (fr) | 2016-10-28 | 2021-05-26 | Bristol Myers Squibb Co | Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha |
US11299494B2 (en) | 2016-11-17 | 2022-04-12 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators |
GB2562702B (en) | 2017-03-06 | 2022-05-18 | Linear Shaped Ltd | Frame and linear shaped charge |
CA3055209A1 (en) * | 2017-03-08 | 2018-09-13 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors, uses, and methods for production thereof |
WO2020222773A1 (en) | 2019-04-30 | 2020-11-05 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
-
2019
- 2019-04-30 WO PCT/US2019/029772 patent/WO2020222773A1/en unknown
- 2019-04-30 KR KR1020217038511A patent/KR20220002488A/ko unknown
- 2019-04-30 IL IL287665A patent/IL287665A/en unknown
- 2019-04-30 AU AU2019443366A patent/AU2019443366A1/en not_active Abandoned
- 2019-04-30 EP EP19723291.1A patent/EP3962475A1/en active Pending
- 2019-04-30 BR BR112021021809A patent/BR112021021809A2/pt unknown
- 2019-04-30 MX MX2021013317A patent/MX2021013317A/es unknown
- 2019-04-30 CN CN201980097711.6A patent/CN114269336A/zh active Pending
- 2019-04-30 CA CA3138473A patent/CA3138473A1/en active Pending
- 2019-04-30 SG SG11202112043PA patent/SG11202112043PA/en unknown
- 2019-04-30 JP JP2021564469A patent/JP2022537877A/ja not_active Abandoned
-
2020
- 2020-04-30 EP EP20725978.9A patent/EP3962476A1/en active Pending
- 2020-04-30 AU AU2020266143A patent/AU2020266143A1/en active Pending
- 2020-04-30 WO PCT/US2020/030608 patent/WO2020223431A1/en unknown
- 2020-04-30 BR BR112021021826A patent/BR112021021826A8/pt unknown
- 2020-04-30 CA CA3138686A patent/CA3138686A1/en active Pending
- 2020-04-30 SG SG11202112018YA patent/SG11202112018YA/en unknown
- 2020-04-30 MX MX2021013318A patent/MX2021013318A/es unknown
- 2020-04-30 CN CN202080046457.XA patent/CN114206333A/zh active Pending
- 2020-04-30 JP JP2021564471A patent/JP7453251B2/ja active Active
- 2020-04-30 KR KR1020217038512A patent/KR20220002489A/ko unknown
- 2020-04-30 MA MA055799A patent/MA55799A/fr unknown
-
2021
- 2021-10-28 IL IL287670A patent/IL287670A/en unknown
- 2021-10-29 CL CL2021002847A patent/CL2021002847A1/es unknown
- 2021-11-22 CO CONC2021/0015614A patent/CO2021015614A2/es unknown
- 2021-11-22 CO CONC2021/0015622A patent/CO2021015622A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021021826A8 (pt) | 2022-06-21 |
MX2021013317A (es) | 2022-01-18 |
KR20220002488A (ko) | 2022-01-06 |
CO2021015614A2 (es) | 2021-12-10 |
CA3138686A1 (en) | 2020-11-05 |
MX2021013318A (es) | 2022-01-31 |
AU2020266143A1 (en) | 2021-12-02 |
AU2019443366A1 (en) | 2021-12-02 |
SG11202112018YA (en) | 2021-11-29 |
CO2021015622A2 (es) | 2022-02-28 |
WO2020222773A1 (en) | 2020-11-05 |
WO2020223431A1 (en) | 2020-11-05 |
CA3138473A1 (en) | 2020-11-05 |
SG11202112043PA (en) | 2021-11-29 |
CN114269336A (zh) | 2022-04-01 |
EP3962476A1 (en) | 2022-03-09 |
BR112021021826A2 (pt) | 2022-01-04 |
MA55799A (fr) | 2022-03-09 |
KR20220002489A (ko) | 2022-01-06 |
IL287665A (en) | 2022-07-01 |
CN114206333A (zh) | 2022-03-18 |
JP2022537877A (ja) | 2022-08-31 |
JP2022537878A (ja) | 2022-08-31 |
EP3962475A1 (en) | 2022-03-09 |
BR112021021809A2 (pt) | 2022-01-04 |
JP7453251B2 (ja) | 2024-03-19 |
IL287670A (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021015614A2 (es) | Terapias de combinación que comprenden inhibidores de apremilast y tyk2 | |
BR112021017495A2 (pt) | Derivado de pirazina e sua aplicação na inibição de shp2 | |
CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
BR112015010477A2 (pt) | combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas | |
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
CR20220325A (es) | Fluoroalquil-oxadiazoles y sus usos | |
BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
EA201790907A1 (ru) | Новые производные пиразолопиримидина в качестве ингибиторов nik | |
ECSP22044525A (es) | Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
BR112021018739A8 (pt) | Composições e métodos para o tratamento de doenças ou distúrbios associados a kras | |
WO2018208793A8 (en) | S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY | |
MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
EA201691555A1 (ru) | Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени | |
BR112022011892A2 (pt) | Composições farmacêuticas intranasais de inibidores de cgrp | |
BR112023000687A2 (pt) | Métodos e combinações de inibidores de kat6 para o tratamento de câncer | |
BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
CL2022001006A1 (es) | Inhibidores de tim-3 y sus usos | |
EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
EA201990508A1 (ru) | ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2 | |
AR116024A1 (es) | Métodos de tratamiento de enfermedades neurodegenerativas | |
BR112022008580A2 (pt) | Métodos para tratar transtornos depressivos |